|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
GENE THERAPY
From INSERM E-0119/UPRES EA-2284, Etablissement
Français du Sang- Bourgogne/Franche-Comté, Besançon,
France; INSERM U463, Institut de Biologie, Nantes, France; and
Haematology Department, Hammersmith Hospital, London, United Kingdom.
To modulate alloreactivity after hematopoietic stem cell
transplantation, suicide gene-expressing donor T cells can be
administered with an allogeneic T-cell-depleted bone marrow graft.
Immune competence of such cells is a critical issue. The impact
of the ex vivo gene transfer protocol (12-day culture period including
CD3/interleukin-2 [IL-2] activation, retroviral-mediated gene
transfer, and G418-based selection) on the anti-Epstein-Barr virus
(EBV) potential of gene-modified cells has been examined. Cytotoxic
(pCTL) and helper (pTh) cell precursor limiting dilution
assays, interferon- Graft versus host (GVH) disease remains a major
source of morbidity and mortality after allogeneic hematopoietic stem
cell (HSC) transplantation. It results from the recognition by mature immunocompetent donor cells present in the graft of alloantigens expressed by the recipients. GVH disease can be efficiently prevented by T-cell depletion of the graft. However, donor T cells significantly contribute to important therapeutic aspects, such as control of graft
rejection, increased graft versus leukemia effect, and antiviral immune
responses.1 Thus, the separation of beneficial and harmful properties of donor T cells remains a major goal of allogeneic HSC transplantation.
In this setting, we have developed a new approach aimed at controlling
donor T cells by administering, together with a T-cell-depleted bone
marrow graft, donor T lymphocytes that have been modified by ex vivo
transfer of the herpes simplex thymidine kinase (HS-tk) gene.2 The expression of such a "suicide" gene allows
for the gene-modified cells (GMCs) to be sensitive to a prodrug,
ganciclovir (GCV). If subsequent GVH disease were to occur, GCV
injection should lead to the specific and selective in vivo depletion
of donor alloreactive GMCs and leave unaltered the other cells. Thus, one could preserve the beneficial effects of the T cells on engraftment and tumor control early after transplantation and throughout the posttransplantation period for patients not experiencing severe GVH
disease. In addition, the GCV-induced selective immunosuppression, restricted to proliferating donor mature GMCs infused with the HSC
graft, should result in a weaker toxicity than the broad
immunosuppressive agents presently used for GVH disease treatment.
Another major complication of HSC transplantation is the
development of Epstein-Barr virus-associated lymphoproliferative disease (EBV-LPD) in the setting of the severe immunosuppressive status
of patients receiving transplants and/or of T-cell
depletion.3 Donor lymphocyte infusions (DLIs) of T cells
remain actually the only efficient treatment of
EBV-LPD.4,5 The use of HS-tk-expressing GMCs should also
contribute to prevent or treat EBV-LPD when administered together with
the HSC graft or when used as donor cells in DLIs.6
We have initiated a phase I/II clinical study aimed at evaluating the
toxicity of HS-tk-expressing GMC infusion and the possibility of
controlling GVH disease through GCV injection.7 In our
first cohort of 12 patients receiving escalating amounts of
HS-tk-expressing donor T cells with a bone marrow graft from an
HLA-identical sibling, 3 developed an EBV-LPD.8 Although
these patients were at high risk for EBV-LPD (recipient age, intensive
conditioning regimen, low T-cell dose, use of cyclosporine and, in one
patient, a second transplantation following ATG
treatment8), an impaired potential of GMCs to control
EBV-LPD could not be excluded. Thus, we evaluated the in vitro
potential of GMCs, ie, cultured cells that have been transduced and
selected, to respond to EBV-infected cells by comparing them with fresh
peripheral blood mononuclear cells (PBMCs) or cultured, nontransduced,
nonselected control cells. This allowed us, using different technical
approaches (limiting dilution assays [LDAs], enzyme-linked immunospot
[ELISPOT] assays, and then flow cytometry [FACS] analysis staining
with tetrameric HLA-A2/EBV peptide complexes) to determine the impact
of the cell culture, transduction, or selection steps on the frequency
of anti-EBV cells in GMC products and on their potential to respond to EBV.
Donors
Donor-derived EBV-transformed B-cell lines
Retroviral vectors Three amphotropic retroviral vectors were used in this study: the G1Tk1SvNa vector,9 provided by Genetic Therapy (Gaithersburg, MD), and the SFCMM39 and LNSN10 vectors, provided by Pr C Bordignon (Milan, Italy). These 3 vectors encode, respectively, the HS-tk and neomycin phosphotransferase II (Neo-R), the HS-tk and truncated NGF receptor ( LNGFR), and, lastly, the LNGFR and Neo-R genes, the first gene being downstream of the viral Moloney long terminal repeat promoter and the second one
being downstream of the SV40 large T-antigen promoter.
Preparation of gene-modified T cells with the G1Tk1SvNa vector Generation of gene-modified T cells required a 12-day culture period, as previously described.11 After isolation by centrifugation over Histopaque-1077 and washes, PBMCs were resuspended in culture medium consisting of RPMI 1640 medium (Biowhittaker), 10% vol/vol human serum (EFS Bourgogne/Franche-Comté, Besançon, France), and recombinant human interleukin-2 (IL-2) (Cetus, Rueil Malmaison, France) at a final concentration of 500 IU/mL. Cells were activated by 10 ng/mL soluble CD3 monoclonal antibody (mAb) (OKT3, Jansen-Cilag, Levallois Perret, France) or with CD3 plus CD28 (B-T3, Diaclone, Besançon, France) mAb-coated beads (4 × 106 beads per 106 cells; Dynal, Compiègne, France) and incubated at 37°C, 5% CO2. After a 3-day culture, the cells were counted and transferred for 24 hours into the retroviral vector-containing medium supplemented with IL-2 (1000 IU/mL) and protamin sulfate (5 µg/mL; Sanofi-Winthrop, Gentilly, France). A cell aliquot was cultured in parallel without the retroviral vector. Twenty-four hours after initiation of transduction, cells were centrifuged, resuspended in culture medium, and incubated for 24 hours at 37°C, 5% CO2. From day 5 to day 12, positive selection was performed by culturing the transduced cells in medium containing G418 (800 µg/mL; Sigma). In parallel, an aliquot of transduced cells was cultured without G418 (transduced, nonselected control cells). Nontransduced, selected cells and nontransduced, nonselected cells (Co cells) were cultured in parallel in medium with or without G418, respectively. At the end of selection (day 12), dead cells were removed by centrifugation over Histopaque-1077. Cell viability was assessed by the trypan blue dye exclusion assay. Viable cells were washed twice with phosphate-buffered saline (PBS; Biowhittaker), resuspended in RPMI 1640 medium, 10% vol/vol human serum, and either used immediately for experiments or cryopreserved with 8% vol/vol dimethylsulfoxide (Braun, Boulogne, France) in liquid nitrogen until use.Preparation of gene-modified T cells with the SFCMM3 vector Cells were activated by soluble CD3 mAb plus IL-2 and transduced as described above for G1Tk1SvNa vector. However, the G418-based selection was replaced by a positive magnetic-based selection at day 5 as follows: cells were stained with culture supernatant of antihuman NGFR mAb-secreting hybridoma (HB8737, clone 20.4, ATCC) and then incubated with goat anti-mouse immunoglobulin G (H+L) microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and positively selected with magnetic-activated cell separation (Miltenyi Biotec), according to the manufacturer's instructions. Selected cells were cultured until day 12 in culture medium with IL-2 (500 IU/mL). Positively selected transduced cells are referred to as "LNGFR+" GMCs.
Preparation of gene-modified T cells transduced with the LNSN vector CD3 plus IL-2-activated cells were transduced from day 3 to day 5 by coculture with the LNSN packaging cell line. Transduced cells were either selected by G418 (800 µg/mL) from day 7 to day 14 or were sorted by immunomagnetic selection at day 7, as described above for SFCMM3-transduced cells, and then cultured until day 14 in the presence of IL-2 (500 IU/mL) with or without G418.Quality controls The sensitivity of GMCs to GCV was assessed as previously described11 and always demonstrated more than 80% inhibition of IL-2-induced proliferation at 1 µg/mL GCV. Transduction efficiency of G1Tk1SvNa-transduced cells, evaluated by quantitative Neo-R gene polymerase chain reaction as previously described,12 was 7.4% ± 1.6% (n = 10) after CD3/IL-2 activation and 11.6% ± 2.0% (n = 5) after activation with CD3/CD28 beads. Transduction efficiencies in SCFMM3- or LNSN-transduced cells, evaluated by indirect staining of transduced cells before magnetic-activated cell separation selection with the antihuman NGFR HB8737 mAb and fluorescein isothiocyanate (FITC)-labeled goat anti-mouse immunoglobulin G (Cappel, ICN Biomedicals, Orsay, France), were 3.6% ± 1.3% (n = 4) and 7.7% ± 2.1% (n = 3), respectively.Limiting dilution assays Sensitization of responder cells at day 0. Responders cells (PBMCs, Co cells, GMCs) from EBV-seropositive or, as negative control, EBV-seronegative donors were plated out in RPMI 1640 medium, 10% vol/vol human serum, at a concentration ranging from 0 to 2 × 105 cells per well (24 replicates per input cell number, final volume 200 µL per well) in round-bottom plates (Sarstedt, Orsay, France) in the presence or absence of 105 freshly irradiated (7.5 Gy) stimulator cells (autologous or allogeneic B-EBV cell lines). Determination of pre-T-helper cell frequencies. A total of 100 µL of CTLL-2 cell suspension was added to each well of a 96-well round-bottom plate (5 × 103 cells per well) containing 100 µL supernatant harvested on day 3 of the LDAs. Cells were incubated during 24 hours in a humidified 37°C, 5% CO2, incubator. One µCi (37 kBq) tritiated thymidine (3H-TdR, Nen Life, Le Blanc Mesnil, France) was added for the last 8 hours of the assay, and the 3H-TdR incorporation was counted by liquid scintillation. The wells exhibiting helper activity were scored as positive if 3H-TdR incorporation exceeded the average plus 3 SD of control wells (supernatant of LDA culture wells containing no responder cells). Frequency values were estimated at 37% of negative wells using the zero term of the Poisson equation.13,14 Determination of precytotoxic cell frequencies. A total of 100 µL of supernatant was removed and replaced by RPMI 1640 medium, 10% vol/vol human serum, and IL-2 (20 IU/mL) at days 3, 6, and 9. On day 12, 10 000 51Cr-labeled (10 µCi [370 kBq] 51Cr per 106 cells; Cis Bio International, Saclay, France) target cells (autologous or allogeneic B-EBV) were added to cultured cells. The plates were spun at 2000 rpm for 2 minutes. After a 4-hour incubation at 37°C, 5% CO2, supernatants were harvested and transferred onto Skatron filters and counted in a gamma counter (Wallac 1470 Wizard, Evry, France). The wells exhibiting cytotoxic activity were scored as positive when the chromium release exceeded the mean release plus 3 SD of control wells (LDA culture wells containing no responder cells). Frequency values were estimated at which 37% of the wells were negative using the zero term of the Poisson equation.13,14 ELISPOT assay The frequency of EBV-specific T cells was also determined with a human interferon- (IFN-) ELISPOT kit (Diaclone), according to the
manufacturer's instructions. Briefly, a 96-well round-bottom plate was
coated with a capture anti-IFN- antibody, incubated for 1 hour at
37°C, 5% CO2, and then washed 3 times with washing buffer. The plate was saturated with 2% bovine serum albumin (BSA; Sigma)/PBS (Biowhittaker) for 1 hour at 37°C to block nonspecific adsorption and then emptied. A total of 2 × 105
responder cells (PBMCs, Co cells, GMCs) were seeded in the absence or
presence of irradiated stimulator cells (autologous or allogeneic B-EBV
cell lines) at a 2:1 ratio in 200 µL RPMI 1640 medium, 10% vol/vol
human serum, and were incubated at 37°C, 5% CO2, for 24 hours. After washing, a biotinylated anti-IFN- antibody was
incubated for 1 hour at 37°C. After 3 washes, streptavidin-alkaline
phosphatase was added for 1 hour at 37°C. The plate was then washed,
placed on an ice bath, and 1% agarose solution was added. Individual IFN--producing cells were detected as blue spots and counted. Data
are expressed as number of spots per 105 cells, according
to the following formula: mean number of spots in stimulated wells  mean number of spots in unstimulated wells. An IL-4 ELISPOT was
performed similarly with a human IL-4 ELISPOT kit (Diaclone). To
demonstrate that the secretion of IFN- or IL-4 was specific of an
anti-EBV response, stimulation of cells from EBV-seronegative donors
with autologous B-EBV cell lines was used as negative controls.
Tetrameric HLA-peptide complex staining Production of phycoerythrin (PE)-labeled tetrameric complexes of HLA-A2 proteins folded with the GLCTLVAML peptide (GLC peptide) from the EBV BMLF (BMFL) lytic protein1 has been previously described.15 A total of 5 × 105 to 10 × 105 cells (PBMCs, Co cells, GMCs) were incubated in 0.1% BSA/PBS at room temperature for 30 minutes with PE-labeled tetrameric complex at a 20 µg/mL final concentration and then labeled with PC5-labeled CD8 mAb (Immunotech, Marseille, France) at 4°C for 30 minutes. After 2 washes in 0.1% BSA/PBS, the cells were fixed in PBS containing 1% formaldehyde (Sigma). Samples were analyzed on a FACSCalibur flow cytometer (Becton Dickinson, Le Pont de Claix, France) using CellQuest software. Analysis was gated on CD8+ lymphocytes. Cells obtained from HLA-A2 EBV-seronegative donors (PBMCs, Co cells, GMCs) were used as negative control with paired samples from EBV-seropositive donors, as previously described.16 The positivity threshold was set in order to get 0.05% positive cells with negative control samples.Apoptosis determination Dioc-6 staining. A total of 0.1 µM Dioc-6 (Interchim, Montluçon, France) was incubated with 5 × 105 cells at the indicated times during 30 minutes at 37°C, before performing a membrane staining (tetrameric complex and PC5-CD8 mAb), as previously described. After staining, cells were washed in 0.1% BSA/PBS and were immediately analyzed by flow cytometry without being fixed in PBS/formaldehyde. Annexin V staining. After performing a membrane staining (tetrameric complex and antibody PC5-CD8), 1 × 106 cells were incubated with 5 µL annexin V-FITC (Immunotech kit, Marseille, France) at 4°C in 500 µL final volume of binding buffer, according to the manufacturer's recommendations. After incubation, the cells were immediately analyzed by flow cytometry without being washed or fixed. Statistical analysis Statistical analyses were performed with the SigmaStat software (Jandel Scientific, Erkrath, Germany). Biologic data were compared using the Student t test or Mann-Whitney rank sum test, depending on Gaussian or non-Gaussian distribution of values.
Gene-modified T cells have a reduced frequency of anti-EBV cytotoxic and helper precursors We first used LDAs, with irradiated autologous B-EBV cell lines as stimulatory cells, to evaluate the frequency of anti-EBV cytotoxic (pCTL) and helper (pTh) cell precursors in GMCs generated from EBV-seropositive individuals. GMCs (transduced and selected cells, cultured during 12 days) were compared with fresh PBMCs and control cells that had been cultured during 12 days but were nontransduced and nonselected (Co cells). As shown in Figure 1, the frequencies of pCTL (A,C,E) and pTh (B,D,F) were lower in Co cells than in PBMCs, suggesting that the 12-day cell culture period was sufficient to affect the EBV-reactive cell frequency. Moreover, frequencies of EBV-specific pCTL and pTh were always lower in GMCs than in Co cells, demonstrating that the transduction and/or selection process further reduced the frequency of EBV-reactive cells. Indeed, anti-EBV pCTLs in Co cells were detectable in 6 of 7 experiments but only in 3 of 10 experiments for GMCs (Figure 2A). Similarly, pTh cells in Co cells were detectable in 3 of 3 experiments but in 2 of 4 experiments only for GMCs (Figure 2B). The observation that both pCTL and pTh were reduced suggests that the loss of EBV-reactive cells affected both CD4+ and CD8+ T cells. Neither pCTL nor pTh frequencies were detectable when responder cells from the 2 EBV-seronegative donors were stimulated with autologous B-EBV cell lines (data not shown). In some experiments, irradiated allogeneic B-EBV cell lines were used in parallel as positive controls for stimulation. As shown in Figure 2, there was a trend for higher pCTL and pTh frequencies against allogeneic B-EBV cell lines than against autologous B-EBV cell lines. Similarly to the situation with autologous B-EBV cell lines, frequencies of pCTL (Figure 2C) and pTh (Figure 2D) reactive against allogeneic B-EBV cell lines were lower in Co cells than in PBMCs and were always further decreased in GMCs, suggesting that the decreased reactivity was not restricted to EBV-specific cells but also affected alloreactive cells.
Impaired anti-EBV function is confirmed by IFN- ELISPOT assay, which has the
advantage of requiring only one day of culture. No spots were observed
in the autologous setting when using cells from the 2 EBV-seronegative
donors (data not shown). As reported in Figure
3, IFN--secreting cell frequencies in
response to autologous B-EBV cell lines were lower in Co cells and in
GMCs than in PBMCs. Similar results were obtained when allogeneic B-EBV
cell lines were used as stimulators instead of autologous cells
(Figure 3).
In 2 experiments, IFN- HLA-A2/GLC peptide tetramer staining demonstrates an early loss of EBV-reactive cells during GMC production LDAs or ELISPOT assays examine T-cell functions. Thus, the frequency of cells expressing EBV-specific T-cell receptors (TCRs) might have been similar within PBMCs, Co cells, and GMCs, while a fraction of EBV-specific cells within Co cells and GMCs could have been anergized and, thus, undetectable in functional assays. The apparent decrease of anti-EBV cell frequency may also have resulted from an induction of activation-induced cell death (AICD) of EBV-reactive cells after B-EBV stimulation during these functional assays. We therefore used a cell phenotype assay based on the staining of EBV-specific T cells with HLA-A2 tetramers complexed with an EBV-derived peptide (GLC) and CD8 mAb. One representative staining is shown in Figure 4A. In agreement with Tan et al,16 frequencies of EBV-reactive T cells in PBMCs were higher when using tetramer staining than with an ELISPOT assay and even higher than with LDAs. However, as observed when using LDAs or ELISPOT assays, the percentage of tetramer+ cells within the CD8 lymphocytes was lower in Co cells than in PBMCs and was even lower in GMCs (Figure 4A). These data demonstrate that the decrease of anti-EBV-reactive T-cell frequencies in Co cells and GMCs was due to a loss of anti-EBV cells during the production of GMCs, resulting in part from the 12-day culture (as assessed by the comparison between PBMCs and Co cells) and in part from the transduction and/or selection process itself (as assessed by the comparison between Co cells and GMCs).
Tetramer staining revealed that the cell loss occurred quickly after CD3/IL-2 activation, because the percentage of tetramer+ CD8+ cells was minimal after 24 to 72 hours of culture and remained close to the detection limit by flow cytometry throughout the 12 days of culture (Figure 4B). Similar early reductions of anti-EBV T cells were observed with LDAs and ELISPOT assays (data not shown). T-cell culture induces rapid early AICD of EBV-reactive cells Because EBV-reactive T cells are mainly CD45RO+ memory T cells,17 we supposed that EBV-specific T cells present in the PBMC suspension were more sensitive to AICD than non-EBV-specific T cells and that they died preferentially from AICD during the first hours of culture, after CD3/IL-2 activation. Thus, we examined the kinetics of apoptosis from day 0 to day 4 by triple staining with Dioc-6, HLA-A2/GLC peptide tetramer, and PC5-CD8. The percentage of Dioc-6 (apoptotic) cells within
CD8+ tetramer+ cells increased quickly after
CD3/IL-2 activation (Figure 5A) and
decreased at day 2. Additional studies, using annexin V-FITC staining,
further confirmed the results obtained with Dioc-6. As shown in Figure
5B, the fraction of annexin V+ (apoptotic) cells within
tetramer+ CD8+ cells increased after
activation, reached a maximum within a similar time frame to that with
Dioc-6, ie, between 24 to 48 hours, and decreased thereafter. When
CD3/IL-2-stimulated cells were compared with nonstimulated cells, the
percentage of annexin V+ cells within tetramer+
CD8+ cells was higher in CD3/IL-2-stimulated cultures than
in nonstimulated cultures, demonstrating that the observed increase of
apoptosis after CD3/IL-2 activation was due to AICD. Moreover, the
percentage of apoptosis in the tetramer+ fraction was
higher than in the tetramer fraction of CD8+
cells, both in nonactivated and activated cultures, demonstrating that
EBV-specific CD8+ cells were more susceptible than other
CD8+ cells to spontaneous apoptosis and AICD (Figure 5B).
At day 12, less than 15% tetramer+ cells were annexin
V+ (data not shown).
Loss of EBV-reactive cells can be prevented in part by an initial CD3/CD28/IL-2 activation Our data point to the initial T-cell activation being an important event responsible for the loss of EBV-reactive cells. However, we have previously demonstrated that replacing the initial CD3/IL-2-induced activation by CD3/CD28 mAb-coated beads and IL-2 could prevent the occurrence of TCRBV repertoire alterations.18 Moreover, CD28 costimulation has been shown to reverse CD3 unresponsiveness19 and to exert antiapoptotic effects.20-22 Thus, we tested whether an initial activation by CD3/CD28 beads and IL-2 could limit the loss of EBV-reactive T cells. Induction of AICD after CD3/CD28/IL-2 activation was lower than after CD3/IL-2 activation, as assessed by the lower percentage of annexin V+ cells among tetramer+ cells (Figure 6), leading to reduced loss of tetramer+ cells during the first 3 days of culture (Figure 7).
An additional effect of CD3/CD28 beads could be directly related to the
proliferation of cells that escaped apoptosis. Thus, we calculated the
cell growth of tetramer+ CD8+ T cells after
CD3/IL-2 or CD3/CD28/IL-2 activation and compared it with the cell
growth of tetramer
G418-based selection, and not the transduction per se, further impairs the EBV-reactive cell frequency As reported above, the frequency of EBV-reactive cells was reproducibly lower in GMCs than in Co cells, demonstrating that, besides an effect of the cell culture itself, an additional effect of transduction and/or selection process accounted for this lower frequency. To further delineate between the effect of transduction and/or selection process on the anti-EBV cell frequency of GMCs, PBMCs were transduced with an HS-tk/LNGFR-coding retroviral vector, SFCMM3, followed by immunomagnetic sorting of LNGFR+
GMCs. Both the LNGFR+ and LNGFR
fractions were compared with HS-tk/Neo-R-transduced, G418-selected GMCs and nontransduced Co control cells. As shown in Table
3, the percentage of
tetramer+ cells was higher in CD8+
LNGFR+ GMCs than in Co control cells, suggesting that
the transduction per se is not deleterious. This also demonstrates that
the expression of HS-tk gene per se is not deleterious to EBV-reactive
T cells.
To further explore the mechanism of G418-induced loss of EBV-reactive
cells, PBMCs were transduced with a vector coding for both the
Administration of donor T cells expressing the HS-tk gene with an HSC transplantation could allow, if GVH disease were to occur, a selective in vivo depletion of these T cells by the use of GCV.2 The administration of low numbers of HS-tk-expressing T cells early following an HLA-identical bone marrow transplantation is associated with no acute toxicity, persistent circulation of the GMCs, and GCV-sensitive GVH disease.8 However, during our phase I/II clinical trial of GMC administration, we observed 3 cases of EBV-LPD.8 Although these patients were at high risk for EBV lymphoma (recipient age, intensive conditioning regimen, low T-cell dose, use of cyclosporine and, in one patient, a second transplantation following ATG treatment8) and despite the observation that one patient developed a complete response after delayed infusion of GMCs,8 we examined whether the process for ex vivo retroviral-based gene transfer could be a parameter affecting the antiviral potential of GMCs. Using 3 different methods (LDAs, ELISPOT assay, and tetramer staining), we demonstrate that the gene transfer process significantly reduces the frequency of EBV-reactive T cells in GMCs as compared with PBMCs and Co cells. We have identified at least 2 critical events responsible for the loss of EBV-reactive cells during GMC production. The first one is a rapid, culture-dependent loss of EBV-specific cells, because Co cells that are activated and cultured for 12 days but are nontransduced and nonselected demonstrate a lower frequency of EBV-reactive cells than PBMCs. Our data demonstrate that the G418-based selection, and not the transduction per se, is the second event responsible for an additional loss of EBV-reactive cells among GMCs with, as a result, a reduced frequency of EBV-reactive T cells in G418-selected GMCs when compared with the Co cells. Using HLA-A2/GLC peptide tetramer staining of CD8+
cells, we show that the ex vivo culture-dependent loss results, at
least for CD8+ cells, from a CD3/IL-2 activation-induced
cell death. This AICD is preferentially restricted to
tetramer+ (EBV-reactive) cells and is observed at a lower
level in tetramer The initial stimulus seems to be critical for preventing the loss of
antigen-specific cells. Because of the known antiapoptotic effect of
CD28 costimulation,20-22 we replaced the CD3/IL-2
activation by CD3/CD28 beads and IL-2. Activation with CD3/CD28/IL-2
induced less AICD of EBV-reactive cells than CD3/IL-2 activation and
partially prevented the culture-induced cell loss of EBV-reactive
cells. These results are in agreement with our observation that
alterations of the TCRBV repertoire observed in GMC cultures
are prevented by replacing the initial CD3/IL-2 activation by CD3/CD28
beads and IL-2.18 In addition, CD3/CD28/IL-2 activation
may preferentially improve the proliferation of tetramer+
cells (ie, memory EBV-specific cells24) over the
tetramer CD3/CD28/IL-2 activation prevents the loss of EBV-reactive cells in
GMCs only when using short-term assays (ie, tetramer staining or
ELISPOT) and not long-term assays (LDAs). This observation may be
explained by the existence of 2 distinct memory T-cell subsets, called
effector memory (Tem) and central memory (Tcm) cells.25 Such cells have also been described in persistent
EBV infection.24 Although both subsets are detectable with
tetramers, only Tem cells, which rapidly secrete IFN- The frequencies of EBV-reactive cells are reproducibly lower in GMCs than in Co cells, suggesting that, in addition to early events following T-cell activation, the transduction and/or the selection process may be another parameter responsible for EBV-specific T-cell loss. Replacing the HS-tk/Neo-R vector (G1Tk1SvNa) by HS-tk/ The observation that the reactivity of G1Tk1SvNa-transduced GMCs and Co cells against allogeneic EBV-transformed cell lines was lower than those of PBMCs is reminiscent of our study demonstrating that concanavalin A-activated, 12-day-cultured murine splenocytes exhibited a reduced alloreactivity in vivo, as evidenced by a delayed onset of GVH disease and a reduced GVH disease-related mortality when injected into mice that underwent allogeneic bone marrow transplantation.27 Whether this loss of alloreactivity results from the same mechanisms as those for the loss of EBV-reactive cells remains unknown. This issue needs to be evaluated in both minor and major histocompatibility settings because alloreactive cells are, at least in part, cross-reactive T cells with antiviral specificities, such as anti-HSV and anti-EBV T cells.28-30 Moreover, because most of the graft versus leukemia effect is apparently due to the recognition of leukemic cells by alloreactive cells31 rather than by tumor-specific T cells, the decreased alloreactivity of GMCs suggests that the graft versus leukemia potential of polyclonal gene-modified T cells might also be decreased when compared with fresh cells. Indeed, a lower than expected frequency of response rates in CML has been reported with DLIs using HS-tk-expressing donor T cells.32 In fact, the improvements we suggest in this paper to enhance the anti-EBV response of gene-modified T cells (use of CD3/CD28 costimulation; cell surface marker-based selection process) might also be beneficial for the antitumor potential of suicide gene-expressing T cells. However, further studies will have to confirm this possibility. In conclusion, we have demonstrated that GMCs have an impaired anti-EBV potential, which may have implications for their ability to control EBV-LPD. The mechanisms involved in this decrease of anti-EBV reactivity involve both culture-dependent phenomena, such as clonal-restricted AICD, and selection-dependent mechanisms. Despite these results, complete response to delayed infusion of GMCs after EBV-LPD has been observed in our study8 and in the study by Bonini et al,6 thus suggesting that anti-EBV reactivity was not completely lost. However, finding ways to prepare GMCs while preserving their immune functions, such as by replacing the initial CD3/IL-2 activation by CD3/CD28/IL-2 activation and preferring a cell surface marker sorting process to Neo-R/G418-based selection, is essential to enhance the therapeutic potential of suicide gene-expressing donor T cells to modulate alloreactivity after HSC transplantation.
Submitted March 26, 2001; accepted September 27, 2001.
Supported by the Programme Hospitalier de Recherche Clinique (PHRC no. 950898), la Ligue Nationale contre le Cancer, l'Association Française contre la Myopathie and the Ministère de l'Enseignement Supérieur et de la Recherche (Centre Réseau de Développement des Thérapies Géniques), l'Association pour la Recherche sur le Cancer (no. 4350), Genetic Therapy, Novartis, and the European Community (Biomed contract no. CT97-2074).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Eric Robinet, Laboratoire de Thérapeutique
Immuno-Moléculaire, INSERM E-0119/UPRES EA-2284, Etablissement
Français du Sang
1. Dazzi F, Goldman JM. Adoptive immunotherapy following allogeneic bone marrow transplantation. Annu Rev Med. 1998;49:329-340[CrossRef][Medline] [Order article via Infotrieve].
2.
Tiberghien P, Reynolds CW, Keller J, et al.
Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation?
Blood.
1994;84:1333-1341
3.
Lucas K, Small TN, Heller G, Dupont B, O'Reilly RJ.
The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation.
Blood.
1996;87:2594-2603 4. O'Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L. Biology and adoptive cell therapy of EBV-associated lymphoproliferative disorders in recipients of marrow allograft. Immunol Rev. 1997;157:195-216[CrossRef][Medline] [Order article via Infotrieve].
5.
Heslop HE, Brenner MK, Rooney CM.
Donor T cells to treat EBV-associated lymphoma.
N Engl J Med.
1994;331:679-680
6.
Bonini C, Ferrari G, Verzeletti S, et al.
HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.
Science.
1997;276:1719-1724 7. Tiberghien P, Brion A, Deconinck E, et al. Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation: a phase I-II study. Hum Gene Ther. 1997;8:615-624[Medline] [Order article via Infotrieve].
8.
Tiberghien P, Ferrand C, Lioure B, et al.
Administration of herpes-simplex thymidine-kinase-expressing donor T cells with a T cell-depleted allogeneic marrow graft.
Blood.
2001;97:63-72
9.
Garin MI, Garrett E, Tiberghien P, et al.
Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene.
Blood.
2001;97:122-129
10.
Mavilio F, Ferrari G, Rossini S, et al.
Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer.
Blood.
1994;83:1988-1997 11. Robinet E, Certoux JM, Ferrand C, et al. A closed culture system for the ex vivo transduction and expansion of human T lymphocytes. J Hematother. 1998;7:205-215[Medline] [Order article via Infotrieve]. 12. Maddens S, Tiberghien P, Contassot E, et al. Development of a competitive PCR method for in vitro and in vivo quantification of herpes simplex virus thymidine kinase and neomycin resistance-expressing cells used in a clinical trial. J Hematother Stem Cell Res. 2000;9:225-236[CrossRef][Medline] [Order article via Infotrieve]. 13. Deacock S, Schwarer A, Batchelor R, Goldman J, Lechler R. A rapid limiting dilution assay for measuring frequencies of alloreactive, interleukin-2-producing T cells in humans. J Immunol Methods. 1992;147:83-92[CrossRef][Medline] [Order article via Infotrieve]. 14. Sharrock CEM, Kaminski E, Man S. Limiting dilution assay of human T cells: a useful clinical tool. Immunol Today. 1990;11:281-286[CrossRef][Medline] [Order article via Infotrieve]. 15. Bodinier M, Peyrat MA, Tournay C, et al. Efficient detection and immuno-magnetic sorting of specific T cells using MHC class I/ peptide multimers with reduced CD8 binding. Nat Med. 2000;6:707-710[CrossRef][Medline] [Order article via Infotrieve].
16.
Tan LC, Gudgeon N, Annels NE, et al.
A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers.
J Immunol.
1999;162:1827-1835
17.
Uehara T, Miyawaki T, Ohta K, et al.
Apoptotic cell death of primed CD45 RO+ T lymphocytes in Epstein-Barr virus-induced infectious mononucleosis.
Blood.
1992;80:452-458
18.
Ferrand C, Robinet E, Contassot E, et al.
Retrovirus-mediated gene transfer in primary T lymphocytes: influence of the transduction/selection process and of the ex vivo expansion on the T cell receptor 19. Shibuya TY, Wei WZ, Zormeier M, et al. Anti-CD3/antiCD28 bead stimulation overcomes CD3 unresponsiveness in patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2000;126:473-479. 20. Colette Y, Razanajaona D, Ghiotto M, Olive D. CD28 can promote T cell survival through a phosphatidylinositol 3-kinase-independent mechanism. Eur J Immunol. 1997;7:3283-3289. 21. Müller Y, Wolf H, Wierenga E, Jung G. Induction of abortive and productive proliferation in resting human T lymphocytes via CD3 and CD28. Immunology. 1999;97:280-286[CrossRef][Medline] [Order article via Infotrieve].
22.
Sepulveda H, Cerwenka A, Morgan T, Dutton RW.
CD28, IL-2-independent costimulatory pathways for CD8 lymphocyte activation.
J Immunol.
1999;163:1133-1142 23. Janossy G, Borthwick N, Lomnitzer R, et al. Lymphocyte activation in HIV-1 infection: predominant proliferative defects among CD45RO+ cells of the CD4 and CD8 lineages. AIDS. 1993;7:613-624[Medline] [Order article via Infotrieve]. 24. Tussey L, Speller S, Gallimore A, Vessey R. Functionally distinct CD8+ memory T cell subsets in persistent EBV infection are differentiated by migratory receptor expression. Eur J Immunol. 2000;30:1823-1829[CrossRef][Medline] [Order article via Infotrieve]. 25. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708-712[CrossRef][Medline] [Order article via Infotrieve]. 26. DiPersio JF, Haug JM, Ritchie JM. Optimal transduction of T cells with chimeric suicide genes using magnetic beads coated with CD3 and CD28 [abstract]. Blood. 2000;96:219a. 27. Contassot E, Murphy W, Angonin R, et al. In vivo alloreactive potential of ex vivo-expanded primary T lymphocytes. Transplantation. 1998;65:1365-1370[CrossRef][Medline] [Order article via Infotrieve]. 28. Gjertsen HA, Lundin KEA, Hansen T, Thorsby E. T cells specific for viral antigens presented by HLA-Dw4 recognize DR13 on allogeneic cells: a possible mechanism for induction of rejection. Transplant Immunol. 1993;1:126-131[CrossRef][Medline] [Order article via Infotrieve]. 29. Levy RB, Jones M, Cray C. HSV-1 enhances GvHR-associated parent anti-F1 alloreactivity in vivo and in vitro. Cell Immunol. 1990;129:1-12[CrossRef][Medline] [Order article via Infotrieve]. 30. Burrows SR, Silins SL, Khanna R, et al. Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leucocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity. Eur J Immunol. 1997;27:1726-1736[Medline] [Order article via Infotrieve]. 31. Dazzi F, Szydlo RM, Goldman JM. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp Hematol. 1999;27:1477-1486[CrossRef][Medline] [Order article via Infotrieve]. 32. Champlin R, Bensinger W, Henslee-Downey J, et al. PhaseI/II study of thymidine kinase (tk)-transduced donor lymphocyte infusions (DLI) in patients with hematologic malignancies [abstract]. Blood. 1999;94:324a.
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  S. Kaneko, S. Mastaglio, A. Bondanza, M. Ponzoni, F. Sanvito, L. Aldrighetti, M. Radrizzani, S. La Seta-Catamancio, E. Provasi, A. Mondino, et al. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes Blood, January 29, 2009; 113(5): 1006 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Hombach, D. Kofler, A. Hombach, G. Rappl, and H. Abken Effective Proliferation of Human Regulatory T Cells Requires a Strong Costimulatory CD28 Signal That Cannot Be Substituted by IL-2 J. Immunol., December 1, 2007; 179(11): 7924 - 7931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Deschamps, P. Mercier-Lethondal, J. M. Certoux, C. Henry, B. Lioure, C. Pagneux, J. Y. Cahn, E. Deconinck, E. Robinet, P. Tiberghien, et al. Deletions within the HSV-tk transgene in long-lasting circulating gene-modified T cells infused with a hematopoietic graft Blood, December 1, 2007; 110(12): 3842 - 3852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Tiberghien Altruistic donor T cells Blood, June 1, 2007; 109(11): 4595 - 4595. [Full Text] [PDF]
|
|
|
|
|
|
F. Ciceri, C. Bonini, S. Marktel, E. Zappone, P. Servida, M. Bernardi, A. Pescarollo, A. Bondanza, J. Peccatori, S. Rossini, et al. Antitumor effects of HSV-TK engineered donor lymphocytes after allogeneic stem-cell transplantation Blood, June 1, 2007; 109(11): 4698 - 4707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Amrolia, G. Muccioli-Casadei, H. Huls, S. Adams, A. Durett, A. Gee, E. Yvon, H. Weiss, M. Cobbold, H. B. Gaspar, et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation Blood, September 15, 2006; 108(6): 1797 - 1808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Berger, M. E. Flowers, E. H. Warren, and S. R. Riddell Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation Blood, March 15, 2006; 107(6): 2294 - 2302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bondanza, V. Valtolina, Z. Magnani, M. Ponzoni, K. Fleischhauer, M. Bonyhadi, C. Traversari, F. Sanvito, S. Toma, M. Radrizzani, et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes Blood, March 1, 2006; 107(5): 1828 - 1836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mesel-Lemoine, M. Cherai, S. Le Gouvello, M. Guillot, V. Leclercq, D. Klatzmann, V. Thomas-Vaslin, and F. M. Lemoine Initial depletion of regulatory T cells: the missing solution to preserve the immune functions of T lymphocytes designed for cell therapy Blood, January 1, 2006; 107(1): 381 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Cohen, Z. Zheng, R. Bray, Y. Zhao, L. A. Sherman, S. A. Rosenberg, and R. A. Morgan Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR J. Immunol., November 1, 2005; 175(9): 5799 - 5808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bonyhadi, M. Frohlich, A. Rasmussen, C. Ferrand, L. Grosmaire, E. Robinet, J. Leis, R. T. Maziarz, P. Tiberghien, and R. J. Berenson In Vitro Engagement of CD3 and CD28 Corrects T Cell Defects in Chronic Lymphocytic Leukemia J. Immunol., February 15, 2005; 174(4): 2366 - 2375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Rettig, J. K. Ritchey, J. L. Prior, J. S. Haug, D. Piwnica-Worms, and J. F. DiPersio Kinetics of In Vivo Elimination of Suicide Gene-Expressing T Cells Affects Engraftment, Graft-versus-Host Disease, and Graft-versus-Leukemia after Allogeneic Bone Marrow Transplantation J. Immunol., September 15, 2004; 173(6): 3620 - 3630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Kolb, C. Schmid, A. J. Barrett, and D. J. Schendel Graft-versus-leukemia reactions in allogeneic chimeras Blood, February 1, 2004; 103(3): 767 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sauce, N. Rufer, P. Mercier, M. Bodinier, J.-P. Remy-Martin, A. Duperrier, C. Ferrand, P. Herve, P. Romero, F. Lang, et al. Retrovirus-mediated gene transfer in polyclonal T cells results in lower apoptosis and enhanced ex vivo cell expansion of CMV-reactive CD8 T cells as compared with EBV-reactive CD8 T cells Blood, August 15, 2003; 102(4): 1241 - 1248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Cavalieri, S. Cazzaniga, M. Geuna, Z. Magnani, C. Bordignon, L. Naldini, and C. Bonini Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence Blood, July 15, 2003; 102(2): 497 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Baum, J. Dullmann, Z. Li, B. Fehse, J. Meyer, D. A. Williams, and C. von Kalle Side effects of retroviral gene transfer into hematopoietic stem cells Blood, March 15, 2003; 101(6): 2099 - 2113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Marktel, Z. Magnani, F. Ciceri, S. Cazzaniga, S. R. Riddell, C. Traversari, C. Bordignon, and C. Bonini Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation Blood, February 15, 2003; 101(4): 1290 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C.M. Straathof, C. M. Bollard, C. M. Rooney, and H. E. Heslop Immunotherapy for Epstein-Barr Virus-Associated Cancers in Children Oncologist, February 1, 2003; 8(1): 83 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Berger, C. A. Blau, T. Clackson, S. R. Riddell, and S. Heimfeld CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy Blood, January 15, 2003; 101(2): 476 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. E. Heslop, F. K. Stevenson, and J. J. Molldrem Immunotherapy of Hematologic Malignancy Hematology, January 1, 2003; 2003(1): 331 - 349. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
, P < .05 as compared with
Co cells.
Bourgogne/Franche-Comté, 1, Bd
Alexander Fleming, 25020 Besançon cedex, France; e-mail:
chain hypervariable region repertoire.
Hum Gene Ther.
2000;11:1151-1164